I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.
- Appointment of Dr. Phillip Dennis as CMO, bringing over two decades of experience in oncology drug development.
- Dr. Dennis's previous experience includes leadership roles at Sanofi and AstraZeneca, contributing to the development of key cancer treatments.
- Dr. Dennis to lead global clinical development efforts, potentially accelerating I-Mab's clinical pipeline progress.
- Focus on key therapies like uliledlimab, givastomig, and ragistomig, which have shown promising data in advanced solid tumors.
- Potential risks associated with a new CMO adjusting to the company's strategic vision and operational dynamics.
- No immediate financial benefits or clinical trial results were reported in the PR, which may not positively impact stock prices in the short term.
"I am pleased to welcome Dr. Phillip Dennis as our Chief Medical Officer. Dr. Dennis brings over two decades of experience in oncology drug development, including his role as a cross-functional leader of the international team that developed a novel PD-L1 inhibitor and his contributions to the development of other assets for lung and other cancers." said Raj Kannan, CEO of I-Mab. "I look forward to partnering with Phillip in further advancing our clinical development pipeline and unlocking the potential of I-Mab for patients and shareholders."
"I am pleased to join I-Mab at this critical juncture in the Company's growth," said Dr. Dennis. " I am excited about the opportunity for uliledlimab, givastomig, and ragistomig, based on data from monotherapy and combination therapy in advanced solid tumors, including lung and gastric cancers, presented at major medical meetings to date. I look forward to working with my accomplished colleagues to support the accelerated development of I-Mab's clinical pipeline."
Before joining I-Mab, Dr. Dennis was Vice President of Lung Cancer Strategy and the Global Project Head for a novel, first-in-class ADC at Sanofi (NASDAQ: SNY). Prior to Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Lead at AstraZeneca (NASDAQ: AZN). In these roles, Dr. Dennis served as the disease strategy head for lung cancer and led the cross-functional development of key assets, including IMFINZI®. Prior to his pharmaceutical career, Dr. Dennis was a widely published professor of Oncology, Medicine, and Pharmacology at Johns Hopkins University. Dr. Dennis received his MS, MD, and PhD degrees from the New York University School of Medicine as part of the Medical Scientist Training Program. Dr. Dennis completed his residency in Internal Medicine and fellowship in Medical Oncology at Johns Hopkins. Dr. Dennis also spent 14 years as a translational researcher at the US National Cancer Institute, achieving tenure as a Senior Investigator. He is an elected member of the American Society for Clinical Investigation and has won several awards, including an NIH Merit Award.
About I-Mab
I-Mab (NASDAQ: IMAB) is a
I-Mab has established operations in the
IMFINZI® is a registered trademark of AstraZeneca.
I-Mab Forward Looking Statements
This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the
I-Mab Contacts
Investors & Media |
Tyler Ehler |
Senior Director, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-appoints-phillip-dennis-md-phd-as-chief-medical-officer-302165433.html
SOURCE I-Mab Biopharma
FAQ
When will Dr. Phillip Dennis join I-Mab as Chief Medical Officer?
What experience does Dr. Phillip Dennis bring to I-Mab?
What are the key therapies Dr. Dennis will focus on at I-Mab?
What is the significance of Dr. Dennis's appointment for I-Mab?